China Unicom Beijing and Huawei Announce World’s First Large-Scale Integrated 5G-Advanced Intelligent Network
BEIJING, Nov. 20, 2024 /PRNewswire/ -- China Unicom Beijing and Huawei held…
Perennial Alzheimer’s Care Village Xi’an Positioned as China’s First and the World’s Sixth Alzheimer’s Care Village
Integrated Western and Eastern medicine, coupled with non-drug intervention therapies, sets international…
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first “Phagogram Day”
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at…
Perennial Alzheimer’s Care Village Xi’an Positioned as China’s First and the World’s Sixth Alzheimer’s Care Village
Integrated Western and Eastern medicine, coupled with non-drug intervention therapies, sets international…
Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial
First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction…
Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial
First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction…
Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial
First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction…
Quantinuum together with Mitsui advance unforgeable quantum tokens over fibre network in first ever trial
First successful delivery of quantum tokens using commercial QKD hardware, demonstrating fast transaction…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…